Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2011, for Innovative Acquisitions Corp. (Note: The input metadata references "PUMA BIOTECHNOLOGY, INC.", but the filing text explicitly identifies the registrant as Innovative Acquisitions Corp.). The company is a Delaware corporation classified as a "shell company" and a "blank check" company. It was formed to pursue a business combination through the acquisition of or merger with an operating business. Since its inception on April 27, 2007, the company has engaged only in organizational efforts and obtaining initial financing, with no active operations or revenue generation.
Key Financial Metrics
| Metric | Q1 2011 | Q1 2010 | Cumulative (Inception to Mar 31, 2011) |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(6,883) | $(4,697) | $(68,871) |
| Cash Balance (End of Period) | $189 | $41 | $189 |
| Total Assets | $189 | $462 (Dec 31, 2010) | $189 |
| Total Liabilities | $2,410 | $0 (Dec 31, 2010) | $2,410 |
| Stockholders' Equity (Deficit) | $(2,221) | $462 (Dec 31, 2010) | $(2,221) |
| Net Cash Used in Operating Activities | $(4,473) | $(6,967) | $(66,461) |
| Net Cash Provided by Financing Activities | $4,200 | $4,600 | $66,650 |
Capital Structure: 3,000,000 shares of common stock outstanding. No preferred stock issued.
Material Changes vs. Prior Period
- Liquidity Decline: Cash on hand decreased from $462 as of December 31, 2010, to $189 as of March 31, 2011, a reduction of $273.
- Liability Increase: Accounts payable increased from $0 to $2,410 during the quarter, primarily due to accrued professional fees.
- Equity Deficit: The company moved from a positive stockholders' equity of $462 to a deficit of $(2,221) due to the net loss incurred in the quarter.
- Expense Growth: General and administrative expenses increased to $6,883 for the quarter ended March 31, 2011, compared to $4,697 in the same period in 2010. These expenses relate to legal, accounting, and audit fees for filing the 2010 Annual Report.
Outlook, Risks, and Management Commentary
- Going Concern: The filing explicitly states that the company has not generated revenue and is unlikely to do so in the immediate future. Substantial doubt exists regarding the company's ability to continue as a going concern. Continuation depends on financial support from shareholders and the ability to obtain equity financing.
- Business Plan: The company intends to identify a target company for a business combination (reverse merger). It has no specific timeline or plan to identify a target. Management anticipates incurring costs for filing reports and investigating acquisitions over the next 12 months.
- Funding Strategy: The company relies on capital contributions from directors and stockholders. During the quarter, directors contributed $4,200. There are no formal agreements guaranteeing future funding, though management and stockholders have indicated an intention to advance funds as needed.
- Risks: Risks include the inability to secure additional financing, the failure to find a suitable acquisition target, and the inherent risks of merging with a financially unstable or early-stage company. The company is also subject to regulations limiting the sale of securities of "blank check" companies.
Investor Verification Checklist
- Identity Discrepancy: Verify why the metadata lists "PUMA BIOTECHNOLOGY, INC." while the filing is for "Innovative Acquisitions Corp."
- Cash Runway: Confirm the company's ability to meet obligations with only $189 in cash and $2,410 in accounts payable.
- Related Party Dependence: Assess the reliability of funding from directors and the rent-free office arrangement with a related party.
- Acquisition Progress: Determine if any specific acquisition targets have been identified or if discussions are merely preliminary.
- Shareholder Contributions: Verify the history and sustainability of capital contributions from existing stockholders to cover operating losses.